marginal significancep = 0.027
However, to date, the potential effects of specific glucose-lowering agents – that is, sulphonylurea (SU), glinides, metformin, thiazolidinediones, insulin, glucagon-like peptide-1 receptor analogs, or dipeptidyl-peptidase-4 (DPP-4) inhibitors – on CV events in patients with T2DM remain uncertain [5] , although some agents, such as metformin and pioglitazone, have been reported to reduce major cardiovascular events in a limited number of newly diagnosed low-risk obese patients (n = 342) with T2DM [6] or to reduce the risk with marginal significance ( p = 0.027) in high-risk patients with T2DM [7] , respectively.